Liver Diseases Clinical Trial
— HEPATOPROTECTOfficial title:
Randomized, Single-blind Study of Remote Ischemic Preconditioning in Hepatectomies
Verified date | October 2022 |
Source | University Hospital, Lille |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
During hepatic transection, it exists a high risk of perioperative blood loss. The haemorrhage and its consequences (hypovolemia and blood transfusion) might impact the short and long term morbidity The vascular control by hepatic pedicle clamping (Pringle's maneuver) or total hepatic vascular exclusion, helps minimizing blood loss and leads to a more extensive hepatic resection. Side effects of vascular control result of ischemia-reperfusion injury (IRI) : these reperfusion lesions results of different mechanisms than those responsible for the ischemic one. IRI cause lesions and postoperative dysfunction of the remaining liver. Among strategies to reduce the adverse effects of IRI : ischaemic preconditioning (IPC) has been described. It can be either mechanical (intermittent hepatic pedicle clamping) or pharmacological (sevoflurane inhalation). Short intermittent vascular occlusions in a organ might produce a resistance to a longer ischaemic period. It is certainly a physiological organ adaptation to tissue hypoxemia, which has a therapeutic potential when targeted. During liver resection, ischaemic preconditioning is realised with periods of hepatic pedicle clamping and unclamping. It decrease morbidity and mortality and prevent postoperative hepatocellular insufficiency due to clamping and IRI at day 5. Ischaemic preconditioning may also be applied remotely. Indeed, it is shown that short ischaemic periods in a target organ can also have a protective effect on distant others. This mechanism involve three signalling pathways : neuronal , humoral and systemic pathways. In a previous randomized study, Kanoria and al, demonstrated that the remote ischaemic preconditioning group has shown significant lower rates of serum transaminases and higher liver clearance (spectrophotometry method) than the control group. A latest study, measuring postoperative prothrombin rates has shown improved liver recovery due to halogen agents such as sevoflurane.
Status | Completed |
Enrollment | 46 |
Est. completion date | January 6, 2020 |
Est. primary completion date | January 6, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Scheduled carcinogenic laparoscopy or laparotomy liver resection - Insured under the social security system - Inclined to comply to the study protocol and its duration. Exclusion Criteria: - Patient under guardianship - Pregnancy or breastfeeding - Severe lower limb vascular disease - Emergency surgery - Contraindication of a treatment from the protocol - Psychological disorder with difficulty to accede the protocol - Absence of written informed consent - Refusal to sign the protocol - Non-registration to the social security system |
Country | Name | City | State |
---|---|---|---|
France | Hop Claude Huriez Chu Lille | Lille |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Indocyanine green clearance | Indocyanine green clearance (%/min) by indocyanine green retention, measured with Limon pulse spectrophotometry method. | at 5 days after liver resection | |
Secondary | Serum transaminases rates | at day 1,day 3 and day 5 post-hepatectomy. | ||
Secondary | Prothrombin rate | at day 5 post-hepatectomy. | ||
Secondary | the Kidney Disease: Improving Global Outcomes (KDIGO) score | The score varies from 1 to 4. | at day 1,day 3 and day 5 post-hepatectomy. | |
Secondary | the Clavien & Dindo score | this classification in order to rank a post operative complications. It consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V) | at day 30 post-hepatectomy | |
Secondary | duration of stay in the hospital. | at day 30 post-hepatectomy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05255042 -
Tissue Models for Liver Disease
|
||
Completed |
NCT04473482 -
Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Recruiting |
NCT03773887 -
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT00345930 -
DILIN - Prospective Study
|
||
Completed |
NCT00148031 -
Improving Hepatitis C Treatment in Injection Drug Users
|
Phase 4 | |
Terminated |
NCT00031135 -
Total Parenteral Nutrition-Associated Liver Disease
|
Phase 2 | |
Completed |
NCT00005305 -
Hepatitis Delta Infections in Hemophiliacs
|
N/A | |
Completed |
NCT00005304 -
Delta Hepatitis and Liver Disease in Hemophiliacs
|
||
Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
Recruiting |
NCT06195917 -
Robotic-assisted Percutaneous Transhepatic Puncture
|
N/A | |
Recruiting |
NCT04551742 -
Social & Contextual Impact on Children Undergoing Liver Transplantation
|
||
Completed |
NCT04782050 -
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Recruiting |
NCT05499585 -
Treating Pediatric NAFLD With Nutrition
|
N/A | |
Terminated |
NCT03396705 -
Liver Regeneration
|
||
Completed |
NCT04341012 -
Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
|
||
Recruiting |
NCT05733832 -
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
|
N/A |